UTHR Stock Summary and Trading Ideas (United Therapeutics | NASDAQ:UTHR)

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

United Therapeutics trades on the NASDAQ stock market under the symbol UTHR.

As of July 10, 2026, UTHR stock price declined to $547.06 with 292,952 million shares trading.

UTHR has a beta of 0.41, meaning it tends to be less sensitive to market movements. UTHR has a correlation of 0.02 to the broad based SPY ETF.

UTHR has a market cap of $23.22 billion. This is considered a Large Cap stock.

Last quarter United Therapeutics reported $782 million in Revenue and $5.82 earnings per share. This fell short of revenue expectation by $-16 million and missed earnings estimates by -$1.01.

In the last 3 years, UTHR traded as high as $609.35 and as low as $208.62.

The top ETF exchange traded funds that UTHR belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.

UTHR has outperformed the market in the last year with a return of +82.3%, while the SPY ETF gained +21.8%. However, in the most recent history, UTHR shares have underperformed the stock market with its stock returning -4.3% in the last 3 month period and +0.8% for the last 2 week period, while SPY has returned +11.4% and +3.6%, respectively.

UTHR support price is $544.17 and resistance is $560.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UTHR shares will trade within this expected range on the day.